ข่าวประชาสัมพันธ์ dronedarone

Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent Atrial Fibrillation

- New Outcomes Trial to Expand Evidence for Dronedarone in a Different AF Population Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st

12 พฤษภาคม 2553 14:04 น.

Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation

- First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing... พ.ย. 52

Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to... ก.ย. 52

ผลวิจัย ATHENA เผยยา Multag(R) ช่วยลดการเกิดภาวะเส้นเลือดในสมองอุดตันในผู้ป่วยโรคหัวใจห้องบนเต้นผิดจังหวะ

ผลการศึกษาดังกล่าวแสดงให้เห็นว่ายา Multag(R) (dronedarone) มีคุณสมบัติช่วยลดความเสี่ยงในการเกิดภาวะเส้นเลือดในสมองอุดตันได้ถึง 34% ในผู้ป่วยที่มีภาวะหัวใจห้องบนเต้นผิดจังหวะหรือหัวใจเต้นรัวซึ่ง... ก.ย. 51

Further Analysis from ATHENA Study Showed That Multaq(R) (Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

- This Analysis Showed That Multaq(R) (dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately... ก.ย. 51

American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation

The ERATO study published today in the American Heart Journal demonstrated, for the first time in patients with permanent atrial... ก.ย. 51

Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone),... พ.ค. 51